Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Chemistry World July 22, 2015 Judy Hayler	The handbook of medicinal chemistry: principles and practice The handbook of medicinal chemistry: principles and practice guides the reader through the R&D process from target validation to late stage clinical trials, via a series of chapters written by individuals in industry and academia.
Chemistry World November 27, 2013 Derek Lowe	Rolling boulders uphill A lot of preclinical projects don't even get off the ground, and many that do still never deliver anything to the development groups.
Chemistry World December 17, 2012 Patrick Walter	RSC acquires rights to Merck Index The Royal Society of Chemistry has acquired the rights to the 'bible' of chemistry, the Merck Index, familiar around the world to medicinal chemists and drug discovery scientists.
Chemistry World December 2008	Column: In the pipeline I've worked on two drug discovery efforts (one right after the other, as fate would have it) whose final compounds differed by essentially one methyl group from the starting points of each project.
Chemistry World August 15, 2013 Lorenzo Caggiano	An introduction to medicinal chemistry (5th edition) An introduction to medicinal chemistry, by Graham Patrick, is exactly that and more. It is an essential text aimed at undergraduates and postgraduates studying aspects of medicinal chemistry.
Chemistry World September 12, 2012 Jon Evans	Drawing maps to hunt for biological gold Pharmaceutical companies should pay more attention to traditional medicine, say UK researchers. This follows their discovery that genetically-similar plants have traditionally been used to treat the same conditions in widely separated parts of the world.
Chemistry World October 2010	Column: In the pipeline Derek Lowe investigates the comeback combinatorial chemistry has made in the field of drug discovery
Chemistry World February 12, 2014 Graham Wynne	Introduction to biological and small molecule drug research and development This text, edited by Ganellin and others, will be of particular interest both to the medicinal chemist who is looking to increase their knowledge beyond the small molecules area, and those with experience in the biologics field.
Chemistry World August 2009 Derek Lowe	Column: In the pipeline The author considers what makes a good looking drug molecule - and how beauty is in the eye of the beholder
Chemistry World August 2007 Derek Lowe	Opinion: In the Pipeline Process chemists just don't get the credit they deserve.
Chemistry World November 2006 Yfke Hager	Careers: Heartfelt Chemistry After working in New Zealand, medicinal chemistry tempted Ashley Jarvis back to the UK. He now works in his dream field.
Chemistry World July 30, 2015 Derek Lowe	A precision instrument? How much do medicinal chemists and their biology colleagues really trust each other's data? In the end, they have to, because drug discovery is a team sport.
Chemistry World December 1, 2014 Derek Lowe	Progress at the pace of the slowest Chemistry is a means to an end in drug research, not an end in itself, and that can take some getting used to. It's worth thinking about where chemistry fits into the big picture.
The Motley Fool May 15, 2007 Brian Lawler	King Fights for Its Empire King Pharmaceuticals announces another good quarter of financial results. Investors should expect more product acquisitions in the coming years.
Chemistry World July 26, 2012 Derek Lowe	Screen shots You might not think that the makeup of a compound screening collection could set off many arguments, but there are a few issues there that will do the trick almost every time.
Chemistry World June 2010	Column: In the pipeline Derek Lowe looks into his crystal ball to see what the future of medicinal chemistry might be
Chemistry World June 2008 Sarah Houlton	Breaking the rules The author finds out about some chemical tricks that can give a new drug the best possible odds of success
Chemistry World April 2009 Derek Lowe	Column: In the pipeline The author considers the problems of addressing drug development out of sequence
Chemistry World November 28, 2013	Put the chemistry back in medicinal chemistry Today, synthetic skill is valued and appreciated much less in medicinal chemistry than in chemical development, though it is equally important for both. Much of the blame lies with the mismeasurement of productivity.
Chemistry World March 2012	Column: In the pipeline Drug discovery requires experimentation, says Derek Lowe. But chemists can be reluctant to stray from the elements they know and love
Bio-IT World November 2006 Kevin Davies	Jubilant Curries Favor with BioPharma The explosion of drug discovery and development operations in India is epitomized by the success of several companies. Quietly building on a decade of experience in computational and bio-IT fields, JBL is rapidly pushing into a suite of drug discovery and development activities.
Chemistry World June 1, 2012 Derek Lowe	Peace, love and understanding You'd think that the chemists and biologists working in drug discovery would understand each other pretty well by now. You would be wrong about that.
Chemistry World April 2011	Molecular Obesity is Weighing Down Drug Discovery Medicinal chemistry's quest for potent drug candidates has resulted in molecules that are too large and too lipophilic for their own good.
Chemistry World November 30, 2012 Andy Extance	Chemists cull compounds using 'intuition' Medicinal chemists might be using far fewer parameters to choose candidate fragments for a screening collection than they think they do. Their choices can be mimicked based on just one or two properties, a team led by researchers at Swiss-headquarted pharmaceutical firm Novartis has found.
Bio-IT World April 2007 Vicki Glaser	Software Solutions for Medicinal Chemistry Driven by advances in chemical synthesis, instrumentation, and high-throughput and high-content screening technology, medicinal chemistry's transition from an art to a science is benefiting from a wealth of new software products, spanning both bio- and cheminformatics.
Chemistry World September 25, 2015 Derek Lowe	Spice up your compounds You and your team are optimizing a lead compound, as medicinal chemists are wont to do -- varying its structure to improve its potency, selectivity and other properties.
Chemistry World June 2011	Column: In the pipeline Chemists are human. Humans are hierarchical. Therefore...well, therefore, you'll find a number of different roles and levels for scientists in a drug company's labs. Here's a rough ordering, from least experienced to most.
Chemistry World November 25, 2014 James Urquhart	Nanomolar chemistry enables 1500 experiments in a single day Chemists have conducted over 1500 chemistry experiments in under a day thanks to a miniaturized, high throughput automation platform they developed for identifying how synthetic molecules react under various conditions.
Chemistry World December 2007 Richard Van Noorden	Surfing Web2O The rapid evolution of the world wide web is creating fresh opportunities - and challenges - for chemistry.
Chemistry World August 2008	Column: In the pipeline Problems develop when there are too few workhorse reactions, which may well generate compounds that are too similar to each other. Are we at that stage now?
Salon.com February 19, 2002 Richard Blow	The chill is gone The once-great Stephen King has been recycling his plots and characters for 20 years now. It's time he made good on his threats to retire...
Chemistry World June 4, 2014 Simon Hadlington	Spider venom pesticide 'harmless to bees' A pesticide based on the venom of a spider, which is toxic to nuisance insects such as aphids and caterpillars, appears to be harmless to honeybees.
The Motley Fool February 27, 2004 Zeke Ashton	King Makes a Comeback The love/hate cycle might be ready to shift again for this pharmaceutical. King Pharmaceuticals was once a beloved growth stock. Then it became an unloved drug stock suffering from intensifying competition, a poor acquisition or two, and an ongoing SEC investigation. The stock has started to come back.
The Motley Fool November 13, 2006 Brian Lawler	King Not Loving Its Shareholders King Pharmaceuticals appears to be a company with stagnating operations, trying to grow sales via licensing or acquiring new drugs, with (at best) a shaky handling of its accounting practices. Investors, take note.